13F Holdings
中文EN

SION Sionna Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2036042 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-55.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-39.0%
ROA-36.4%
ROIC (approx.)-44.5%
Asset turnover—

Leverage & solvency

Liabilities / assets8.6%
Debt / equity0.00x
Current ratio13.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$60.26M$57.29M
SG&A expense$28.72M$13.27M
Operating income-$88.98M-$70.56M
Income tax$0$0
Net income-$75.27M-$61.69M
EBITDA-$88.33M-$69.89M
EPS (basic)-1.88-15.99
EPS (diluted)-1.88-15.99
Weighted avg. shares (diluted)39.96M3.86M
Balance sheet
Cash & equivalents$58.45M$38.75M
Current assets$241.42M$150.99M
PP&E, net$2.23M$2.47M
Total assets$325.95M$185.75M
Current liabilities$11.71M$10.42M
Total liabilities$19.12M$19.10M
Shareholders' equity$306.83M-$163.71M
Shares outstanding44.72M4.72M
Cash flow statement
Operating cash flow-$66.30M-$52.79M
Capital expenditure$377,000$27,000
Free cash flow-$66.67M-$52.81M
Investing cash flow-$118.75M-$126.91M
Financing cash flow$205.71M$178.97M
Depreciation & amortization$647,000$668,000
Stock-based compensation$12.07M$3.71M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.